File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

TitleA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Authors
Issue Date2018
Citation
Cell, 2018, v. 175, n. 4, p. 984-997.e24 How to Cite?
AbstractImmune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive. Here, we leveraged single-cell RNA sequencing (scRNA-seq) from 33 melanoma tumors and computational analyses to interrogate malignant cell states that promote immune evasion. We identified a resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion. The program is expressed prior to immunotherapy, characterizes cold niches in situ, and predicts clinical responses to anti-PD-1 therapy in an independent cohort of 112 melanoma patients. CDK4/6-inhibition represses this program in individual malignant cells, induces senescence, and reduces melanoma tumor outgrowth in mouse models in vivo when given in combination with immunotherapy. Our study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance. Single-cell sequencing of checkpoint-inhibitor-resistant melanomas identifies predictive signatures to guide therapeutic approaches to overcome immunotherapy resistance.
Persistent Identifierhttp://hdl.handle.net/10722/318742
ISSN
2023 Impact Factor: 45.5
2023 SCImago Journal Rankings: 24.342
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJerby-Arnon, Livnat-
dc.contributor.authorShah, Parin-
dc.contributor.authorCuoco, Michael S.-
dc.contributor.authorRodman, Christopher-
dc.contributor.authorSu, Mei Ju-
dc.contributor.authorMelms, Johannes C.-
dc.contributor.authorLeeson, Rachel-
dc.contributor.authorKanodia, Abhay-
dc.contributor.authorMei, Shaolin-
dc.contributor.authorLin, Jia Ren-
dc.contributor.authorWang, Shu-
dc.contributor.authorRabasha, Bokang-
dc.contributor.authorLiu, David-
dc.contributor.authorZhang, Gao-
dc.contributor.authorMargolais, Claire-
dc.contributor.authorAshenberg, Orr-
dc.contributor.authorOtt, Patrick A.-
dc.contributor.authorBuchbinder, Elizabeth I.-
dc.contributor.authorHaq, Rizwan-
dc.contributor.authorHodi, F. Stephen-
dc.contributor.authorBoland, Genevieve M.-
dc.contributor.authorSullivan, Ryan J.-
dc.contributor.authorFrederick, Dennie T.-
dc.contributor.authorMiao, Benchun-
dc.contributor.authorMoll, Tabea-
dc.contributor.authorFlaherty, Keith T.-
dc.contributor.authorHerlyn, Meenhard-
dc.contributor.authorJenkins, Russell W.-
dc.contributor.authorThummalapalli, Rohit-
dc.contributor.authorKowalczyk, Monika S.-
dc.contributor.authorCañadas, Israel-
dc.contributor.authorSchilling, Bastian-
dc.contributor.authorCartwright, Adam N.R.-
dc.contributor.authorLuoma, Adrienne M.-
dc.contributor.authorMalu, Shruti-
dc.contributor.authorHwu, Patrick-
dc.contributor.authorBernatchez, Chantale-
dc.contributor.authorForget, Marie Andrée-
dc.contributor.authorBarbie, David A.-
dc.contributor.authorShalek, Alex K.-
dc.contributor.authorTirosh, Itay-
dc.contributor.authorSorger, Peter K.-
dc.contributor.authorWucherpfennig, Kai-
dc.contributor.authorVan Allen, Eliezer M.-
dc.contributor.authorSchadendorf, Dirk-
dc.contributor.authorJohnson, Bruce E.-
dc.contributor.authorRotem, Asaf-
dc.contributor.authorRozenblatt-Rosen, Orit-
dc.contributor.authorGarraway, Levi A.-
dc.contributor.authorYoon, Charles H.-
dc.contributor.authorIzar, Benjamin-
dc.contributor.authorRegev, Aviv-
dc.date.accessioned2022-10-11T12:24:27Z-
dc.date.available2022-10-11T12:24:27Z-
dc.date.issued2018-
dc.identifier.citationCell, 2018, v. 175, n. 4, p. 984-997.e24-
dc.identifier.issn0092-8674-
dc.identifier.urihttp://hdl.handle.net/10722/318742-
dc.description.abstractImmune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive. Here, we leveraged single-cell RNA sequencing (scRNA-seq) from 33 melanoma tumors and computational analyses to interrogate malignant cell states that promote immune evasion. We identified a resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion. The program is expressed prior to immunotherapy, characterizes cold niches in situ, and predicts clinical responses to anti-PD-1 therapy in an independent cohort of 112 melanoma patients. CDK4/6-inhibition represses this program in individual malignant cells, induces senescence, and reduces melanoma tumor outgrowth in mouse models in vivo when given in combination with immunotherapy. Our study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance. Single-cell sequencing of checkpoint-inhibitor-resistant melanomas identifies predictive signatures to guide therapeutic approaches to overcome immunotherapy resistance.-
dc.languageeng-
dc.relation.ispartofCell-
dc.titleA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cell.2018.09.006-
dc.identifier.pmid30388455-
dc.identifier.scopuseid_2-s2.0-85055549585-
dc.identifier.volume175-
dc.identifier.issue4-
dc.identifier.spage984-
dc.identifier.epage997.e24-
dc.identifier.eissn1097-4172-
dc.identifier.isiWOS:000449100600013-
dc.identifier.f1000734323393-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats